From what 6 stock analysts predict, the share price for Repligen Corp (RGEN) might increase by 37.21% in the next year. This is based on a 12-month average estimation for RGEN. Price targets go from $160 to $225. The majority of stock analysts believe RGEN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
RGEN is a stock in Healthcare which has been forecasted to be worth $193.06 as an average. On the higher end, the forecast price is $225 USD by Raghuram Selvaraju from HC Wainwright & Co. and on the lower end RGEN is forecasted to be $160 by from .
These are the latest 20 analyst ratings of RGEN.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Conor McNamara RBC Capital | Outperform | $205 | Reiterates | Sep 26, 2024 |
Brandon Couillard Wells Fargo | Overweight | $180 | Initiates | Aug 27, 2024 |
Robert Wasserman Benchmark | Hold | Reiterates | Aug 5, 2024 | |
Elizabeth Garcia UBS | Buy | $185 | Maintains | Jul 31, 2024 |
Conor McNamara RBC Capital | Outperform | $190 | Reiterates | Jul 31, 2024 |
Rachel Vatnsdal JP Morgan | Overweight | $200 | Maintains | Jul 31, 2024 |
Jacob Johnson Stephens & Co. | Overweight | $170 | Reiterates | Jul 30, 2024 |
Justin Bowers Deutsche Bank | Buy | $155 | Upgrade | Jun 26, 2024 |
Subbu Nambi Guggenheim | Neutral | Initiates | Jun 18, 2024 | |
Rachel Vatnsdal JP Morgan | Overweight | $200 | Maintains | May 2, 2024 |
Daniel Arias Stifel | Buy | $207 | Maintains | Feb 22, 2024 |
Paul Knight Keybanc | Overweight | $220 | Maintains | Feb 15, 2024 |
Tycho Peterson JP Morgan | Overweight | $210 | Maintains | Dec 20, 2023 |
Robert Wasserman Benchmark | Hold | Downgrade | Dec 4, 2023 | |
Elizabeth Garcia UBS | Buy | $170 | Maintains | Nov 2, 2023 |
Paul Knight Keybanc | Overweight | $210 | Maintains | Nov 1, 2023 |
Conor McNamara RBC Capital | Outperform | $200 | Maintains | Nov 1, 2023 |
Daniel Arias Stifel | Buy | $165 | Maintains | Nov 1, 2023 |
Tycho Peterson JP Morgan | Overweight | $180 | Maintains | Oct 17, 2023 |
Conor McNamara RBC Capital | Outperform | $191 | Reiterates | Sep 8, 2023 |
When did it IPO
1990
Staff Count
1,783
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Olivier Loeillot
Market Cap
$7.88B
In 2023, RGEN generated $638.8M in revenue, which was a decrease of -20.31% from the previous year. This can be seen as a signal that RGEN's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Repligen Corporation (NASDAQ:RGEN) will present at three upcoming investor conferences, highlighting its focus on bioprocessing technology.
Why It Matters - Repligen Corporation's participation in investor conferences can boost visibility, attract potential investors, and signal confidence in its growth prospects, impacting stock performance.
Summary - Repligen (RGEN) is not expected to meet earnings expectations in its upcoming report due to lacking key performance indicators. Investors should prepare for this outcome.
Why It Matters - Repligen's lack of key ingredients for an earnings beat may indicate weaker performance, potentially leading to a decline in stock price and investor confidence.
Summary - The global Peptide Therapeutics market was valued at $42.1B in 2023 and is projected to reach $56.2B by 2030, with a CAGR of 4.2%, driven by technological advances in therapy development.
Why It Matters - The projected growth of the peptide therapeutics market indicates potential investment opportunities, driven by technological advancements and increasing demand for targeted therapies.
Summary - Repligen Corporation (NASDAQ:RGEN) has opened the Repligen Training & Innovation Center at its Waltham headquarters, enhancing its focus on bioprocessing technology.
Why It Matters - The launch of the Repligen Training & Innovation Center enhances Repligen's bioprocessing capabilities, potentially driving growth, innovation, and market competitiveness, which can positively impact stock performance.
Summary - Repligen Corporation (NASDAQ:RGEN) will present at the Wells Fargo Healthcare Conference from September 4-6, with CEO Olivier Loeillot speaking on September 6 at 8:45 a.m. ET.
Why It Matters - Repligen's presentation at a key healthcare conference could influence investor sentiment and stock performance, showcasing its bioprocessing advancements and leadership in the sector.
Summary - Repligen has made an acquisition offer to Maravai LifeSciences Holdings, which has a market value of $2.2 billion, according to sources.
Why It Matters - Repligen's acquisition offer for Maravai could signal growth opportunities in the biotech sector, potentially increasing Repligen's market share and affecting stock valuations.